INTRODUCTION {#s1}
============

During 1955 to 1956, a large epidemic of water-borne hepatitis was reported in New Delhi, India.^[@R1]^ The epidemic was initially believed to be related to hepatitis A. However, subsequent testing of stored sera from this epidemic and another epidemic from 1978 to 1979 failed to demonstrate a serological marker, neither for hepatitis A nor for hepatitis B.^[@R2],[@R3]^ The new agent was named non-A non-B hepatitis virus.^[@R4]^ Later, the agent was renamed hepatitis E virus (HEV) and in 1990 its genome was cloned.^[@R5]^

Acute HEV infection often presents with jaundice, dark urine, anorexia, enlarged and tender liver, elevated ALT, and abdominal pain and tenderness.^[@R6]^ It is associated with nausea, vomiting and fever, and is selflimiting in most cases with a low mortality rate and very low rates of progression to chronic liver disease.^[@R6]^

However, the severity and mortality rates are higher in pregnant women (up to 20%)^[@R6],\ [@R7]^, organ recipients,^[@R8],\ [@R9]^ and in patients who receive blood products.^[@R10]^ HEV infection is associated with abortion, stillbirths and low birth weight in infected pregnant women.^[@R6],\ [@R7]^

The prevalence of HEV is as high as 70% in Egypt.^[@R11]^ The prominent route of HEV transmission is fecal--oral in endemic countries ^[@R6],\ [@R12]^ which leads to medium to large epidemics, and the majority of sporadic cases in these countries.^[@R2]^ Parenteral or perinatal transmission are less common.^[@R6]^

Person-to-person transmission is distinctly uncommon.^[@R13],\ [@R14]^HEV, primarily a zoonotic disease, rarely occurs in industrialized countries.^[@R15]^ HEV is detected serologically through the titration of anti-IgG antibodies in suspected patients.

Iran is classified among the endemic regions, as in several studies the seroprevalence of HEV has been reported to be above 5%. Suspected outbreaks have been reported in Iran.^[@R16]^ HEV infection was for the first time reported in pregnant women in Kermanshah in 1991.

^[@R17]^ In 1992, 154 cases were reported from Lordegan.^[@R16],\ [@R17]^ Studies on blood donors in Iran have demonstrated that the prevalence of HEV infection varies, ranging from 7.8% in Tehran^[@R18]^ and Tabriz^[@R19]^ to 11.5% in Khuzestan.^[@R20]^

However, the HEV seroprevalence is more varied in population-based studies.

The reported seroprevalence ranges from 3.8% in Isfahan^[@R21]^ 9 to 7.3% in Mazandaran among adults between the ages of 20 to 25 years ^[@R22]^ and lastly, from 9.6% and 9.3%, respectively in 2004 and 2008 in Nahavand.^[@R23],\ [@R24]^

HEV seroprevalence is believed to be higher among patients with chronic liver or kidney disease. A study in Tabriz reported that HEV was serologically prevalent in 27.5% of patients with chronic liver disease.^[@R25]^ However another report from the same city demonstrates that seroprevalence of HEV among hemodialysis patients is 7.4%.^[@R26]^ A study in Ahvaz shows that HEV seroprevalence is 13.5% in drug addicts ^[@R27]^ not much higher than the general population, and it is amazingly low among Iranian soldiers (1.1%).^[@R28]^

The apparent variation in previous studies on HEV seroprevalence has prompted largescale population-based studies in this regard. The merit of the present study lies in its relatively large sample size and its distribution across two large provinces in Iran.

MATERIALS AND METHODS {#s2}
=====================

Design and setting: {#s2-1}
-------------------

This secondary analysis is a cross-sectional study that was conducted in 2009 in the Digestive Disease Research Center (DDRC) of Tehran University of Medical Sciences. The source survey of this study was performed on the general population of Iran and sera were collected in 2006.

In the original survey, participants were selected from the general population of three provinces of Iran: Golestan in Northeast Iran, Tehran in North central and Hormozgan in Southern Iran. The survey included Iranian nationals between the ages of 18 and 65 who were permanent inhabitants of their households.

Randomly selected from all participants in the source survey, this study has included 1423 adults who resided in two provinces of Tehran and Golestan. Baseline information on Iran and the three provinces studied is given in [Table 1](#T1){ref-type="table"}

###### Census information on Iran in the three provinces studied\*.

  ---------- ------------------------ ---------------- ------------------- ------------------ --------------
             **Area (km** ^2^ **)**   **Population**   **Percent rural**   **Percent male**   **Literacy**
  Tehran     18,814                   13,422,366       8.7%                51.4%              91.3%
  Golestan   20,367                   1,617,087        50.8%               49.7%              82.1%
  Iran       1,648,195                70,495,782       31.5%               50.9%              84.0%
  ---------- ------------------------ ---------------- ------------------- ------------------ --------------

**\***Source: Iran national population and housing census, 2006,

[http://www.sci.org.ir/portal/faces/public/sci_en , reproduced from Merat et al](http://www.sci.org.ir/portal/faces/public/sci_en , reproduced from Merat et al).^[@R29]^

Sampling and sample size {#s2-2}
------------------------

The original survey was targeted at liver diseases that had an estimated prevalence of about 0.5%; therefore, 4596 participants were enrolled by clustered random sampling and 100 clusters were selected from each province. Each cluster consisted of 20 to 25 eligible subjects who lived within a block of adjacent households and the first household of the cluster was selected by random sampling. Plasma samples were then obtained and a questionnaire was filled in which common risk factors were recorded. Sampling methods and data collection has been explained in detail elsewhere.^[@R29]^

For HEV, the estimated prevalence was 9% ^[@R30],\ [@R31]^ and based on our calculations, a sample size of 1400 would be sufficient (alpha=0.05). Thus, we selected 25% of the originally collected sera for our study by systematic random sampling.

Baseline data: {#s2-6}
--------------

Baseline data in this study included sex, age, educational level, marital status, birth rank, and possible risk factors such as history of blood transfusion, non IV-drug addiction, IV-drug addiction, previous surgery, phlebotomy, tattooing, imprisonment and hepatitis among family members.

Laboratory tests: {#s2-3}
-----------------

Serum samples from selected participants were transferred to the Iran Blood Transfusion Organization (IBTO) Research Center, where they were tested for total anti-HEV antibodies (Dia.Pro Diagnostic Bioprobes srl, Milano, Italy).

Statistical analysis: {#s2-4}
---------------------

The age specific seroprevalence of HEV was calculated in each province. Data were then weighted based on the population size in each province. Weighted prevalence of HEV in the entire population and weighted logistic regression were calculated to investigate the potential effect of determinants on HEV seroprevalence. All analyses were done by SPSS 16.0 (SPSS, Inc., Chicago, IL).

Ethics {#s2-5}
------

The study was approved by the Institutional Review Board of the Digestive Disease Research Center, Tehran University of Medical Sciences. Questionnaires and serological tests were registered unanimously. All participants signed an informed consent.

RESULTS {#s3}
=======

A total of 1423 serum samples were included in the study. The demographics of the study population in the two provinces are presented in [Table 2](#T2){ref-type="table"}.

###### Characteristics of study participants.

  ---------- -------------------------- ------------------------------- ------------------ ------------------- -------------------------
             **Subjects interviewed**   **Samples randomly selected**   **Percent male**   **Percent rural**   **Mean age±SD (years)**
  Tehran     2561                       789 (55.4%)                     39.7%              2.7%                35.3±13.3
  Golestan   2035                       634 (44.6%)                     34.4%              37.1%               41.1±12.8
  Total      4596                       1423 (100%)                     37.3%              18.0%               37.9±13.4
  ---------- -------------------------- ------------------------------- ------------------ ------------------- -------------------------

The prevalence of HEV seropositivity was 7.3% in Tehran, 9.2% in Golestan and 7.4% in the entire sample, adjusted for the populations of both provinces and residential location (urban or rural; [Table 3](#T3){ref-type="table"}).

###### The prevalence of anti-HE V antibodies in the two provinces.

  ------------------- -------------- ---------------- ---------------
                      **Tehran\***   **Golestan\***   **Total\*\***
  Anti-HEV antibody   7.3%           9.2%             7.4%
  Male                7.6%           8.3%             7.7%
  Female              6.9%           11.0%            7.2%
  ------------------- -------------- ---------------- ---------------

**\*** Percentages adjusted for location (urban or rural).

**\*\***Totals adjusted for population of provinces and location (urban or rural).

The difference between males and females was not significant.

The prevalence of HEV seropositivity increased by age in both provinces, both residential locations (urban and rural) and both genders ([Figures 1](#F1){ref-type="fig"} to [3](#F3){ref-type="fig"}).
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In univariate logistic regression, the determinants of HEV seropositivity consisted of age, subjects' educational levels, marital status, mother's educational level, and history of traditional phlebotomy ([Table 4](#T4){ref-type="table"}). In multivariate logistic regression however, only age and history of traditional phlebotomy remained in the model ([Table 5](#T5){ref-type="table"}).

###### Determinants of HE V Seropositivity in univariate analysis.

  ----------------------------- ---------------- ------------------------- --------------------
                                **Number (%)**   **Anti-HEV positive**\    ***p*** **-value**
                                                 **Odds ratio (95% CI)**   

  **Province**\                 \                \                         \
  Tehran\                       58 (7.4%)\       1\                        \
  Golestan                      70 (11.0%)       1.52 (0.95-2.44)\*        0.08

  **Gender**\                   \                \                         \
  Male\                         46 (8.7%)\       1\                        \
  Female                        82 (9.2%)        0.93 (0.52-1.69)\*\*      0.81

  **Location**\                 \                \                         \
  Urban\                        95 (8.1%)\       1\                        \
  Rural                         33 (12.9%)       1.99 (0.79-4.86)^\#^      0.15

  **Age** (for each 10 years)   37.7±13.4        1.66 (1.33-2.08)\*\*      \<0.001

  **Education**\                \                \                         \
  \<6 years\                    66 (14.1%)\      1\                        \
  6 years or more               44 (6.3%)        0.31 (0.17-0.57)\*\*      \<0.001

  **Marital status**\           \                \                         \
  Unmarried\                    4 (1.8%)\        1\                        \
  Married                       105 (11.1)       5.48 (1.76-17.13)\*\*     0.003

  **Father\'s education**\      \                \                         \
  \<6 years\                    46 (8.3%)\       1\                        \
  6 years or more               12 (5.2%)        0.56 (0.26-1.18)\*\*      0.13

  **Mother\'s education**\      \                \                         \
  \<6 years\                    52 (8.9%)\       1\                        \
  6 years or more               6 (3.0%)         0.32 (0.12-0.83)\*\*      0.02

  **Blood transfusion**\        \                \                         \
  No\                           96 (9.0%)\       1\                        \
  Yes                           14 (14.0%)       1.66 (0.71-3.90)\*\*      0.25

  **Addiction**\                \                \                         \
  No\                           100 (9.2%)\      1\                        \
  Yes                           10 (12.7%)       1.84 (0.51-6.64)\*\*      0.35

  **IV addiction**\             \                \                         \
  No\                           57 (7.3%)\       1\                        \
  Yes                           1 (20.0%)        3.25 (0.28-37.59)\*\*     0.35

  **Surgery**\                  \                \                         \
  No\                           53 (8.4%)\       1\                        \
  Yes                           57 (10.7%)       1.43 (0.79-2.59)\*\*      0.23

  **Traditional phlebotomy**\   \                \                         \
  No\                           40 (6.0%)\       1\                        \
  Yes                           18 (15.8%)       3.20 (1.64-6.25)\*\*      0.001

  **Tatooing**\                 \                \                         \
  No\                           54 (7.4%)\       1\                        \
  Yes                           4 (7.0%)         0.97 (0.30-3.12)\*\*      0.96

  **Imprisonment**\             \                \                         \
  No\                           57 (7.4%)\       1\                        \
  Yes                           1 (7.1%)         0.99 (0.10-9.62)\*\*      0.99

  **Family history**\           \                \                         \
  No\                           48 (6.8%)\       1\                        \
  Yes                           9 (13.2%)        1.91 (0.79-4.61)\*\*      0.15
  ----------------------------- ---------------- ------------------------- --------------------

\*OR weighted by location (urban or rural).

\*\*OR weighted by both province population and location (urban or rural).

\# OR weighted by province population.

###### Determinants of HE V seropositivity by multivariate analysis.

  ------------------------- ------------------- --------------------
                            **OR (95% CI)\***   ***p*** **-value**
  Age (for each 10 years)   1.59 (1.26-2.02)    \<0.001
  Traditional phlebotomy    2.28 (1.13-4.60)    0.021
  ------------------------- ------------------- --------------------

**\***OR weighted by both province population and location (urban or rural).

DISCUSSION {#s4}
==========

The results of our study on the overall HEV prevalence are concordant with several previous population-based studies and reports among blood donors in Iran.^[@R18]-[@R21],\ [@R23],[@R24]^ The HEV prevalence in Iran is apparently higher than developed countries (0.4%-3.9%), higher than the prevalence in Israel (2.8% in Jews and 1.8% in Arabs) ^[@R32]^ or Turkey (3.8%),^[@R33]^ but lower than Kurdish refugees in Iraq (14.8%),^[@R34]^ blood donors (16.4%), the general population (18.8%) in Saudi Arabia,^[@R35],\ [@R36]^ and finally the general population in Pakistan (17.5%).^[@R37]^

Variations in reports somehow reflect different levels of exposure in different regions. However, alternative evidence may cast doubt on this assumption. It is reported that anti-IgG serological tests have 100% specificity but varied sensitivity.^[@R38]^ The fact that HEV seroprevalence in developed countries and in Egypt is higher than expected raises the possibility of cross-reaction with other antibodies. On the other hand, seroprevalence is lower than expected in endemic regions like India, which indicates the existence of false negative results. Agreement between various tests is moderate ^[@R39]^ and several ELISA kits have been previously withdrawn from the market due to high proportions of false negatives.^[@R38]^ The ELISA kit used in this study is documented to be 100% specific, 96% sensitive and 99% accurate. Still, the possibility of inaccurate estimation of HEV seroprevalence in different populations should not be neglected.

HEV seropositivity has been mainly reported in males.^[@R6],\ [@R20]^However, most studies in Iran fail to demonstrate any significant difference between the two genders.^[@R18],\ [@R21]\ ,[@R22],\ [@R25]^ The results of one study show that HEV seroprevalence is significantly higher among females.^[@R23]^ In our study, although more prevalent among males, the seroprevalence is not significantly different between the two genders.

The results of some studies in Iran have demonstrated no significant difference in HEV seropositivity between urban and rural residents ^[@R21],\ [@R25],\ [@R27]^which is supported in the current study.

Previous studies have shown that HEV seropositivity peaks among 15-35 year-olds and is not seen in children.^[@R2],\ [@R25],\ [@R27]^ However, other studies in Tehran, Khuzestan, and Nahavand show that HEV seroprevalence is highest among 35-49 year olds.^[@R18],\ [@R20],\ [@R23]^ Also, in two other studies, the HEV seroprevalence is highest among those over 50.^[@R19],\ [@R21]^ The results of our study confirm the previous studies in Iran and show that age is a significant risk factor for HEV seroprevalence.

Results of previous studies in Iran show that HEV seropositivity is lower in the educated compared to the uneducated, but the difference is not significant.^[@R21],\ [@R23],\ [@R25],\ [@R27],\ [@R28]^ In two studies, the difference in seroprevalence between educational level of subjects and their parents is significant.^[@R19],\ [@R22]^ Our results support the first finding that the difference between the educated and the uneducated is not significant.

The results of a study in 2004 in Tabriz failed to show any significant association between history of blood transfusion and HEV seroprevalence which negates the possibility of parenteral transmission for HEV.^[@R26]^ On the other hand, the reported high prevalence of HEV seropositivity among drug addicts, particularly among injecting drug users in Ahvaz, supports the possibility.^[@R27]^ In our study, the significantly high seropositivity in subjects who presented with a history of traditional phlebotomy supports this hypothesis, although the results on other related risk factors such as history of blood transfusion, addiction, imprisonment, surgery and surgery are insignificant, probably due to the high proportion of missing data.

Insignificant results on the role of familial history of hepatitis support the assumption that person-to-person communication is uncommon in HEV hepatitis.^[@R13],\ [@R14]^

The main limitation of the current study is that the seroprevalence among vulnerable groups, including pregnant women and immunosuppressed patients, has not been investigated. Despite the low cost-effectiveness of vaccines for the prevention of HEV infection, further studies are needed to investigate the efficiency of vaccination in groups who are vulnerable to HEV infection in Iran.
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